Response from CGB, page-375

CGB)Formerly Queensland Bauxite, the company officially changed its name to Cann Global at the start of this year to reflect the changed nature and scale of its activities in the medical cannabis and hemp industries.Although it still currently retains an interest in two bauxite projects in Queensland and New South Wales, the company transformed from a mineral exploration company with a minor interest in medical cannabis to an international medical cannabis and all-natural foods company in the short space of six months.It is legally licensed to grow and cultivate hemp, running hemp seed farms in four Australian states from which it produces premium hemp seed oil, oil capsules, smoothie blends and hemp milk under the label ‘VitaHemp’.It has a large network of wholesale and retail clients in Australia and more recently, in China and Vietnam.In addition, the company signed an MoU with Israeli company PharmoCann to manufacture its cannabis products and collaborate on clinical trials.It also recently entered into a strategic collaboration and supply agreement with Canadian company Bonify.In February 2019, Cann Global announced a signed MoU with Australian pharmaceutical company Biohealth Pharmaceuticals, which is expected to move its production schedule of medical cannabis formulations and nutraceutical hemp food consumables forward to the first half of 2019.As well as Australia, the partners are planning to target established markets in Hong Kong, Japan and Korea.